Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for SCLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2021. Start Trial.
Date Value
June 30, 2026 -4.491M
March 31, 2026 9.144M
December 31, 2025 17.95M
September 30, 2025 -11.57M
June 30, 2025 -8.805M
March 31, 2025 -3.084M
December 31, 2024 -7.091M
September 30, 2024 -4.662M
June 30, 2024 4.761M
March 31, 2024 -11.20M
December 31, 2023 8.278M
Date Value
September 30, 2023 -38.86M
June 30, 2023 43.41M
March 31, 2023 10.63M
December 31, 2022 57.74M
September 30, 2022 -6.943M
June 30, 2022 -12.59M
March 31, 2022 39.96M
December 31, 2021 -110.83M
September 30, 2021 -1.457M
June 30, 2021 0.0156M
March 31, 2021 140.16M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Oramed Pharmaceuticals, Inc. -2.265M
Semnur Pharmaceuticals, Inc. 2.074M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Veru, Inc. -0.0519M